Investor Relations

Press Releases

Date Title and Summary View
Oct 31, 2017

Data Suggests Twirla May Decrease Mean Length of Bleeding and Spotting Episodes

Oct 16, 2017
Detailed Bleeding Profile Data Provide Helpful Information for Patient Counseling PRINCETON, N.J., Oct. 16, 2017 – Agile Therapeutics, Inc., (NASDAQ: AGRX), a women’s healthcare company, today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational
Oct 10, 2017

Company Also Announces Four New Patents Granted for its Novel Transdermal Contraceptive Dosing Regimens

Oct 02, 2017
PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday, October 10, 2017 in New York City. Members of Agile's executive team will review clinical data and
Sep 28, 2017
PRINCETON, N.J., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract based on the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch (AG200-15) has been selected for a
Sep 14, 2017

Presentation Scheduled on Tuesday, September 26th, 2017 at 11:30 AM ET

Sep 07, 2017
PRINCETON, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract presenting data from the Phase 3 SECURE study of its investigational low-dose combined hormonal contraceptive patch (AG200-15) has been
Aug 22, 2017

Presentation Scheduled on Tuesday, September 12th, 2017 at 9:10 AM ET

Aug 16, 2017

Presentation Scheduled on Thursday, September 7th, 2017 at 8:00 AM PT

Aug 03, 2017
PRINCETON, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women's healthcare company, today announced the pricing of its underwritten public offering of 5,333,334 shares of its common stock at a public offering price of $3.75 per share.